These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28606733)

  • 21. S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balance.
    Grum-Schwensen B; Klingelhöfer J; Beck M; Bonefeld CM; Hamerlik P; Guldberg P; Grigorian M; Lukanidin E; Ambartsumian N
    BMC Cancer; 2015 Feb; 15():44. PubMed ID: 25884510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy.
    Yan L; Tan Y; Chen G; Fan J; Zhang J
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor microenvironment and lymphocyte infiltration.
    Rahir G; Moser M
    Cancer Immunol Immunother; 2012 Jun; 61(6):751-9. PubMed ID: 22488275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
    Bianchi G; Borgonovo G; Pistoia V; Raffaghello L
    Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune response regulation in the tumor microenvironment by hypoxia.
    Labiano S; Palazon A; Melero I
    Semin Oncol; 2015 Jun; 42(3):378-86. PubMed ID: 25965356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
    Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
    Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.
    Payne KK; Bear HD; Manjili MH
    Future Oncol; 2014 Aug; 10(10):1779-94. PubMed ID: 25303057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune control in hepatocellular carcinoma development and progression: role of stromal cells.
    Sprinzl MF; Galle PR
    Semin Liver Dis; 2014 Nov; 34(4):376-88. PubMed ID: 25369300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive cells in tumor immune escape and metastasis.
    Liu Y; Cao X
    J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncology meets immunology: the cancer-immunity cycle.
    Chen DS; Mellman I
    Immunity; 2013 Jul; 39(1):1-10. PubMed ID: 23890059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of murine tumour growth through CD8
    Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
    Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulation in cancer.
    Hegmans JP; Aerts JG
    Curr Opin Pharmacol; 2014 Aug; 17():17-21. PubMed ID: 25011112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic Barriers to T Cell Function in Tumors.
    Sugiura A; Rathmell JC
    J Immunol; 2018 Jan; 200(2):400-407. PubMed ID: 29311381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cell therapy in solid tumors].
    Ravaud A
    Bull Cancer; 2001 Jan; 88(1):91-100. PubMed ID: 11182658
    [No Abstract]   [Full Text] [Related]  

  • 36. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
    Bhargava A; Mishra D; Banerjee S; Mishra PK
    Immunotherapy; 2012 Jul; 4(7):703-18. PubMed ID: 22853757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment.
    Wang J; Li D; Cang H; Guo B
    Cancer Med; 2019 Aug; 8(10):4709-4721. PubMed ID: 31222971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting regulatory T cells in tumors.
    Liu C; Workman CJ; Vignali DA
    FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of Basic Immunology for Clinical Investigators.
    Stephen B; Hajjar J
    Adv Exp Med Biol; 2017; 995():1-31. PubMed ID: 28321810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.
    Kalathil SG; Thanavala Y
    Cancer Immunol Immunother; 2016 Jul; 65(7):813-9. PubMed ID: 26910314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.